



Derivatization of a tris-oxazole using Pd-catalyzed coupling reactions of a 5-bromooxazole moiety

Kazuaki Shibata^a, Masahito Yoshida^b, Takayuki Doi^{a,b,*}, Takashi Takahashi^{a,*}

^a Department of Applied Chemistry, Tokyo Institute of Technology, 2-12-1 Ookayama, Meguro, Tokyo 152-8552, Japan

^b Graduate School of Pharmaceutical Sciences, Tohoku University, 6-3 Aza-Aoba, Aramaki, Aoba-ku, Sendai 980-8578, Japan

ARTICLE INFO

Article history:

Received 14 December 2009

Revised 15 January 2010

Accepted 20 January 2010

Available online 25 January 2010

Keywords:

Oxazoles

Pd-catalyzed reaction

Amination

Alkoxylation

Cross-coupling

ABSTRACT

Modification at the C5 position of an oxazole ring contained in a 2,4-concatenated tris-oxazole by Pd-catalyzed coupling reactions was performed. Novel Pd-catalyzed amination and alkoxylation of a 5-bromooxazole derivative as well as Suzuki–Miyaura coupling and Migita–Stille coupling have been demonstrated. A wide variety of functional groups, including aryl, heteroaryl, primary and secondary amines, and phenol, were introduced in the 5-bromooxazole moiety in moderate to excellent yields using Pd(OAc)₂/S-PHOS or Pd(OAc)₂/X-PHOS as a catalyst.

© 2010 Elsevier Ltd. All rights reserved.

Oxazole-containing natural products are attracting attention for their fascinating structures and broad range of biological activity.¹ Many researchers have investigated their total synthesis and that of their derivatives.² These natural products consist of not only a single oxazole but also two or more oxazoles concatenated at the 2- and 4-positions³ such as in telomestatin (**1**),^{4,5} YM-216391 (**2**),^{6,7} and ulapualide A (**3**)^{8,9} (Fig. 1). Since the oxazoles in these natural products possess a hydrogen, a methyl, or a phenyl group at the C5 position, these substituents may affect their biological activities. To elucidate the structure–activity relationships on the basis of the substituents on the 2,4-concatenated oxazoles, we need to develop an efficient synthetic method for introducing a wide variety of functional groups at the C5 position of an oxazole moiety.

Our strategy is therefore to introduce a 5-bromooxazole moiety in a 2,4-concatenated tris-oxazole in advance and selectively activate the bromide by Pd-catalyzed coupling reactions in the later stage of synthesis toward efficient diversification (Fig. 2). Herein, we report the synthesis and Pd-catalyzed coupling reactions of 5-bromooxazole-containing tris-oxazole that corresponds to the synthetic intermediate of the natural product telomestatin.^{10–12}

Preparation of tris-oxazole **11** containing a 5-bromooxazole moiety is shown in Scheme 1. Commercially available Boc–Cys(*t*-Bu)–OH (**4**) was converted to 4-cyanooxazole **5** by the modified

Harran procedure.¹³ Boc protection of the carbamate with (Boc)₂O, followed by treatment with NH₃/MeOH and aqueous H₂O₂, provided amide **6** (68%) in two steps. After conversion of **6** to tetra-carbamate with (Boc)₂O, methanolysis at the C terminus with K₂CO₃/MeOH, followed by a selective removal of the Boc group




Figure 1. Tris-oxazole-containing natural products.

* Corresponding authors. Fax: +81 3 5734 2884.

E-mail addresses: doi_taka@mail.pharm.tohoku.ac.jp (T. Doi), ttak@apc.titech.ac.jp (T. Takahashi).





Figure 2. Our synthetic strategy for 5-functionalized tris-oxazole derivatives by Pd-catalyzed coupling reactions.



Scheme 1. Reagents and conditions: (a) (i) aminomalnonitrile *p*-toluenesulfonate, EDCl, Py., rt, 20 h, (ii) *t*-BuONO, CuBr₂, CH₃CN, 0 °C to rt, 2 h, 28% (two steps); (b) (i) (Boc)₂O, NEt₃, DMAP, CH₂Cl₂, rt, 24 h, (ii) NH₃/MeOH, aq H₂O₂, dioxane, rt, 2 h, 68% (two steps); (c) (i) (Boc)₂O, DMAP, CH₃CN, rt, 2 h, (ii) K₂CO₃, THF–MeOH, rt, 3 h, (iii) TFA (2.0 equiv), CH₂Cl₂, rt, 6 h, 90% (three steps); (d) Me₃SnOH, (CH₂Cl)₂, 80 °C, 6 h, 92%; (e) **9**, PyBrop, DIEA, CH₂Cl₂, rt, 3 h, 90%; (f) (i) Burgess reagent, THF, 70 °C, 12 h, (ii) DBU, BrCCl₃, CH₂Cl₂, rt, 12 h, 76% (two steps).

with 2 equiv of TFA, afforded the desired 5-bromooxazole **7** (90% overall). Although hydrolysis of **7** with LiOH in THF–MeOH–H₂O gave a complex mixture, methyl ester **7** was converted to acid **8** by treatment with trimethyltin hydroxide (92%).¹⁴ Amidation of **8** with amine **9** using PyBrop/DIEA provided bis-oxazole amide **10** (90%). Finally, cyclodehydration of **10** using Burgess reagent,¹⁵ followed by a treatment with BrCCl₃/DBU,¹⁶ afforded the expected tris-oxazole **11** (76%).


In our initial attempt at modification at the C5 position of an oxazole, we investigated various Pd-catalyzed coupling reactions of 5-bromooxazole **7**. Results are summarized in Table 1. Migita–Stille coupling of **7** with PhSnBu₃ in the presence of PdCl₂(CH₃CN)₂ proceeded at 80 °C to give **12a** in 94%. Coupling reaction

Table 1
Pd-catalyzed and Cu-mediated cross-coupling reactions of 5-bromooxazole **7**

Entry	R	Nucleophile	Catalyst	Additive	Product	Yield (%)
1 ^a	Ph	PhSnBu ₃	PdCl ₂ (CH ₃ CN) ₂	—	12a	94
2 ^b	Me	Me ₄ Sn	POPd	CuI	12b	85
3 ^c	Ph	PhB(OH) ₂	PdCl ₂ (PPh ₃) ₂	KF	12a	90
4 ^d	C ₈ H ₁₇ NH	C ₈ H ₁₇ NH ₂	Pd(OAc) ₂	K ₃ PO ₄	12c	80
5 ^e	CF ₃	FSO ₂ CF ₂ CO ₂ Me	—	CuI HMPA	12d	81

Reagents and conditions: (a) PdCl₂(CH₃CN)₂ (5 mol %), PhSnBu₃ (1.5 equiv), DMF (0.2 M), 80 °C, 12 h; (b) POPd (5 mol %), CuI (15 mol %), Me₄Sn (1.5 equiv), DMF (0.2 M), 80 °C, 12 h; (c) PdCl₂(PPh₃)₂ (5 mol %), PhB(OH)₂ (1.5 equiv), KF (2 equiv), dioxane (0.2 M), 60 °C, 12 h; (d) Pd(OAc)₂ (5 mol %), X-PHOS (10 mol %), C₈H₁₇NH₂ (2 equiv), K₃PO₄ (3 equiv), DME (0.2 M), 60 °C, 24 h; (e) CuI (1.2 equiv), FSO₂CF₂CO₂Me (5 equiv), HMPA (5 equiv), DMF (0.05 M), 70 °C, 12 h. POPd = PdCl₂[(*t*-Bu)₂P(OH)]₂, X-PHOS = 2-Dicyclohexylphosphino-2',4',6'-triisopropylbiphenyl.

Table 2
Suzuki–Miyaura cross-coupling of **11** with phenyl boronic acid




Entry	Pd cat.	Base	Temp (°C)	Time (h)	Yield (%)
1	PdCl ₂ (PPh ₃) ₂	KF	60	16	Trace
2	Pd(Pr-Bu) ₃	KF	60	16	Trace
3	Pd(OAc) ₂ , L-1	KF	60	16	62
4	Pd(OAc) ₂ , L-2	KF	60	16	73
5	Pd(OAc) ₂ , L-3	KF	60	16	92
6	Pd(OAc) ₂ , L-3	KF	110	0.5	95
7	Pd(OAc) ₂ , L-3	K ₃ PO ₄	60	16	79

Reagents and conditions: Pd catalyst (10 mol %) or Pd(OAc)₂ (10 mol %)/ligand (20 mol %), PhB(OH)₂ (1.5 equiv), base (KF or K₃PO₄) (2 equiv), dioxane (0.2 M). L-1 = 2-(Di-*t*-butylphosphino)-2'-methylbiphenyl, L-2 = 2-(Dicyclohexylphosphino)-2'-methylbiphenyl, L-3 = 2-Dicyclohexylphosphino-2',6'-dimethoxybiphenyl (S-PHOS).

with Me₄Sn in the presence of POPd¹⁷/CuI yielded **12b** (85%; entry 2). Suzuki–Miyaura reaction of **7** with PhB(OH)₂ in the presence of PdCl₂(PPh₃)₂/KF afforded the expected **12a** in excellent yield (90%; entry 3). Racemization at the α-position of the modified cysteine residue is suppressed (<2%) under the reaction conditions (See Supplementary data).¹⁸

Table 3
Scope of the boronic acids in Suzuki–Miyaura reaction of **11** and other Pd-catalyzed cross-coupling reactions



Entry	Nucleophile	Conditions	Product	R ¹	Yield (%)
1	14a 	i	15a (R ² = OMe)		91
2	14b 	i	15b (R ² = OMe)		80
3	14c 	i	15c (R ² = OMe)		74
4	14d 	i	15d (R ² = OMe)		62
5	14e 	i or ii	15e (R ² = OMe)		i: 53 ii: 84
6	14f 	i or ii	15f (R ² = OMe)		i:30 ii:91
7	14g 	ii	15g (R ² = OMe)		63
8	14h 	ii	15h (R ² = OMe)		68
9	14i 	iii	15i (R ² = OMe)		70
10	14j 	iv	16j (R ² = NHC ₈ H ₁₇)		70
11	14k 	iv	15k (R ² = OMe)		65
12	14l 	iv	15l (R ² = OMe)		69
13	14m 	v	15m (R ² = OMe)		43

Reagents and conditions: (i) KF (2 equiv), dioxane (0.2 M), 110 °C (MW), 0.5 h; (ii) KF (2 equiv), DME (0.2 M), 80 °C, 16 h; (iii) dioxane (0.2 M), 60 °C, 16 h; (iv) K₃PO₄ (3 equiv), DME (0.2 M), 80 °C, 24 h; (v) K₃PO₄ (2 equiv), dioxane (0.2 M), 80 °C, 16 h; nucleophile was used as 1.5 equiv (entries 1–9, and 13), 4 equiv (entry 10) and 2 equiv (entries 11 and 12).

Furthermore, we introduced an amino group at the C5 position of the oxazole by Pd-catalyzed amination.¹⁹ Amination of **7** with octylamine in the presence of Pd(OAc)₂/X-PHOS at 60 °C provided the desired 5-(octylamino)oxazole **12c** (80%; entry 4). The methyl ester remains intact and racemization at the α -position of the modified cysteine residue is suppressed (<3%) under the reaction conditions.¹⁸ Fluorinated small molecules are attractive compounds for medicinal chemistry and drug discovery.²⁰ Therefore,

we also examined trifluoromethylation. Cu(I)-mediated nucleophilic substitution of **7** with FSO₂CF₂CO₂Me provided 5-(trifluoromethyl)oxazole **12d** (81%; entry 5).²¹

According to the above result (Table 1, entry 3), we investigated the Suzuki–Miyaura coupling reaction of tris-oxazole **11** with PhB(OH)₂. Results are summarized in Table 2. Reaction in the presence of PdCl₂(PPh₃)₂/KF (entry 1) did not proceed; nor did reaction in the presence of Pd(Pt-Bu₃)₂ (entry 2). In view of the difficulty of

oxidative addition of **11** onto Pd(0) catalyst, we used more electron-rich ligands in this cross-coupling reaction because Buchwald and co-workers have reported that biaryl monophosphine ligands are highly effective for Suzuki–Miyaura reaction of heteroaryl halides with aryl boronic acids; reaction using Pd(OAc)₂/Buchwald monophosphine ligands (L-1, L-2, and L-3 in the Table)²² proceeded to yield the desired **13** (entries 3–7). In particular, the use of L-3 (S-PHOS) yielded **13** in 92% yield (entry 5). After further optimization, cross-coupling reaction was completed within 30 min under microwave irradiation to yield **13** (95%; entry 6).

With optimized reaction conditions for Suzuki–Miyaura reaction of **11** in hand, we next examined a range of boronic acids and other cross-coupling reactions such as ethynylation, amination, and alkoxylation. Results are summarized in Table 3. *p*-Substituted aryl boronic acids **14a–d** yielded the corresponding products **15a–d** (62–91%; entries 1–4). *p*-Hydroxyphenyl derivative **14e** reacted incompletely (53%) even under microwave irradiation (entry 5). However, reaction in the presence of Pd(OAc)₂/X-PHOS/KF under conventional heating (80 °C, 16 h) was completed to yield **15e** (84%). When *p*-formylphenyl boronic acid **14d** was used for the coupling reaction, a small amount of debrominated product **15n** (R¹ = H, R² = OMe) was observed (<5%). Turning from microwave irradiation to conventional heating (DME, 80 °C, 16 h) in the presence of Pd(OAc)₂/X-PHOS provided the desired coupling products **15f–h** in acceptable yields (entries 6–8). Ethynylation of **11** by Migita–Stille coupling (entry 9) proceeded at 60 °C in the presence of Pd(OAc)₂/X-PHOS to yield **15i** (70%).

Amination of **11** with primary and secondary amines (entries 10–12) using K₃PO₄ at 80 °C afforded the corresponding coupling products **16j**, **15k**, and **15l** (65–70%). In entry 10, **16j** was obtained as a sole product formed by transamidation of the methyl ester with the less-hindered primary amine **14j**. In alkoxylation of **11**, coupling reaction of phenol **14m** with K₃PO₄ in the presence of Pd(OAc)₂/X-PHOS provided the expected **15m** (43%; entry 13). In this reaction, β-elimination of the *St*-Bu group was observed.²³

In summary, we have demonstrated the modification of the C5 position of an oxazole ring contained in a 2,4-concatenated tris-oxazole derivative by means of Pd-catalyzed cross-coupling reactions. Novel Pd-catalyzed amination and alkoxylation of 5-bromooxazole as well as Suzuki–Miyaura coupling have been achieved. In the presence of Pd(OAc)₂/S-PHOS or Pd(OAc)₂/X-PHOS, a wide variety of functional groups, such as aryl, heteroaryl, primary and secondary amines, and phenol, were introduced in the 5-bromooxazole moiety in moderate to excellent yields. These modifications could be applied to diversification of natural products containing a 2,4-concatenated tris-oxazole. The synthesis of telomestatin derivatives utilizing this method is underway in our laboratory.

Acknowledgments

This work was supported by the New Energy and Industrial Technology Development Organization. We also thank the partial support by the Global COE Program (Chemistry, TokyoTech).

Supplementary data

Supplementary data associated with this article can be found, in the online version, at doi:10.1016/j.tetlet.2010.01.064.

References and notes

- Plamer, D. C.; Venkatraman, S. *The Chemistry of Heterocyclic Compounds. In Oxazoles: Synthesis, Reactions and Spectroscopy. Part A*; Wiley & Sons: Hoboken, NJ, 2004.
- (a) Yeh, V. S. C. *Tetrahedron* **2004**, *60*, 11995–12042; (b) Riego, E.; Hernández, D.; Albericio, F.; Alvarez, M. *Synthesis* **2005**, 1907–1922; (c) Jin, Z. *Nat. Prod. Rep.* **2006**, *23*, 464–496.
- (a) Wipf, P.; Lim, S. J. *Am. Chem. Soc.* **1995**, *117*, 558–559; (b) Yokokawa, F.; Asano, T.; Shioiri, T. *Org. Lett.* **2000**, *2*, 4169–4172; (c) Chattopadhyay, S. K.; Kempson, J.; Mcneil, A.; Pattenden, G.; Reader, M.; Rippon, D. E.; Waite, D. *Perkin Trans. 1* **2000**, 2415–2428; (d) Nicolaou, K. C.; Rao, P. B.; Hao, J. L.; Reddy, M. V.; Rassias, G.; Huang, X. H.; Chen, D. Y. K.; Snyder, S. A. *Angew. Chem., Int. Ed.* **2003**, *42*, 1753–1758; (e) Chattopadhyay, S. K.; Biswas, S.; Pal, B. K. *Synthesis* **2006**, 1289–1294; (f) Smith, T. E.; Kuo, W.-H.; Bock, V. D.; Roizen, J. L.; Balkus, E. P.; Theberge, A. B. *Org. Lett.* **2007**, *9*, 1153–1155; (g) Hernández, D.; Vilar, G.; Riego, E.; Cañedo, L. M.; Cuevas, C.; Albericio, F.; Álvarez, M. *Org. Lett.* **2007**, *9*, 809–811; (h) Hernández, D.; Riego, E.; Albericio, F.; Álvarez, M. *Eur. J. Org. Chem.* **2008**, 3389–3396.
- Shin-ya, K.; Wierzbka, K.; Matsuo, K.; Ohtani, T.; Yamada, Y.; Furihata, K.; Hayakawa, Y.; Seto, H. *J. Am. Chem. Soc.* **2001**, *123*, 1262–1263.
- Doi, T.; Yoshida, M.; Shin-ya, K.; Takahashi, T. *Org. Lett.* **2006**, *8*, 4165–4167.
- Sohda, K.; Nagai, K.; Yamori, T.; Suzuki, K.; Tanaka, A. *J. Antibiot.* **2005**, *58*, 27–31.
- (a) Deeley, J.; Pattenden, G. *Chem. Commun.* **2005**, 797–799; (b) Deeley, J.; Bertram, A.; Pattenden, G. *Org. Biomol. Chem.* **2008**, *6*, 1994–2010.
- Roesener, J. A.; Sheuer, P. J. *J. Am. Chem. Soc.* **1986**, *108*, 846–847.
- (a) Chattopadhyay, S. K.; Pattenden, G. *Tetrahedron Lett.* **1998**, *39*, 6095–6098; (b) Panek, J. S.; Liu, P. J. *Am. Chem. Soc.* **2000**, *122*, 11090–11097; (c) Pattenden, G.; Ashweek, N. J.; Baker-Glenn, C. A. G.; Walker, G. M.; Yee, J. G. K. *Angew. Chem., Int. Ed.* **2007**, *46*, 4359–4363.
- (a) Schnürch, M.; Flasiak, R.; Khan, A. F.; Spina, M.; Mihovilovic, M. D.; Stanetty, P. *Eur. J. Org. Chem.* **2006**, 3283–3307; (b) Inoue, M. *Mini-Rev. Org. Chem.* **2008**, *5*, 77–84.
- (a) Hoarau, C.; Kerdaniel, A. D. F.; Bracq, N.; Grandclaudon, P.; Couture, A.; Marsais, F. *Tetrahedron Lett.* **2005**, *46*, 8573–8577; (b) Flegeau, E. F.; Popkin, M. E.; Greaney, M. F. *Org. Lett.* **2008**, *10*, 2717–2720; (c) Besselièvre, F.; Mahuteau-Betzer, F.; Grierson, D. S.; Piguel, S. J. *Org. Chem.* **2008**, *73*, 3278–3280; (d) Verrier, C.; Martin, T.; Hoarau, C.; Marsais, F. *J. Org. Chem.* **2008**, *73*, 7383–7386; (e) Ohnmacht, S. A.; Mamone, P.; Culshaw, A. J.; Greaney, M. F. *Chem. Commun.* **2008**, 1241–1243; (f) Verrier, C.; Hoarau, C.; Marsais, F. *Org. Biomol. Chem.* **2009**, *7*, 647–650; (g) Yoshizumi, T.; Satoh, T.; Hirano, K.; Matsuo, D.; Orita, A.; Otera, J. *Tetrahedron Lett.* **2009**, *50*, 3273–3276.
- (a) Hodgetts, K. J.; Kershaw, M. T. *Org. Lett.* **2002**, *4*, 2905–2907; (b) Hodgetts, K. J.; Kershaw, M. T. *Org. Lett.* **2003**, *5*, 2911–2914; (c) Boger, D. L.; Miyauchi, H.; Du, W.; Hardouin, C.; Fecik, R. A.; Cheng, H.; Hwang, I.; Hedrick, M. P.; Leung, D.; Acevedo, O.; Guimarães, C. R. W.; Jorgensen, W. L.; Cravatt, B. F. *J. Med. Chem.* **2005**, *48*, 1849–1856; (d) Hämmerle, J.; Schnürch, M.; Stanetty, P. *Synlett* **2007**, 2975–2978.
- Jeong, S.; Chen, X.; Harran, P. G. *J. Org. Chem.* **1998**, *63*, 8640–8641.
- Nicolaou, K. C.; Estrada, A. A.; Zak, M.; Lee, S. H.; Safina, B. S. *Angew. Chem., Int. Ed.* **2005**, *44*, 1378–1382.
- (a) Burgess, E. M.; Penton, H. R.; Taylor, E. A. *J. Org. Chem.* **1973**, *38*, 26–31; (b) Wipf, P.; Miller, C. P. *J. Org. Chem.* **1993**, *58*, 1575–1578; (c) Aguilar, E.; Meyers, A. I. *Tetrahedron Lett.* **1994**, *35*, 2477–2480.
- Williams, D. R.; Lowder, P. D.; Gu, Y.-G.; Brooks, D. A. *Tetrahedron Lett.* **1997**, *38*, 331–334.
- (a) Li, G. Y. *Angew. Chem., Int. Ed.* **2001**, *40*, 1513–1516; (b) Wolf, C.; Lerebours, R. *J. Org. Chem.* **2003**, *68*, 7077–7084; (c) Wolf, C.; Lerebours, R. *Org. Lett.* **2004**, *6*, 1147–1150; (d) Xu, H.; Ekoue-Kovi, K.; Wolf, C. *J. Org. Chem.* **2008**, *73*, 7638–7650.
- A small amount of racemization was detected by HPLC with UV area (214 nm) after acylation of **12a** and **12c** with *D*- and *L*-mandelic acid.
- Surry, D. S.; Buchwald, S. L. *Angew. Chem., Int. Ed.* **2008**, *47*, 6338–6361.
- (a) Muller, F.; Taeh, C.; Diederich, F. *Science* **2007**, *317*, 1881–1886; (b) Kirk, K. L. *Org. Process Res. Dev.* **2008**, *12*, 305–321; (c) Purser, S.; Moore, P. R.; Swallow, S.; Gouverneur, V. *Chem. Soc. Rev.* **2008**, *37*, 320–330.
- (a) Chen, Q.-Y.; Wu, S.-W. *J. Chem. Soc., Chem. Commun.* **1989**, 705–706; (b) Qing, F.-L.; Fan, J.; Sun, H.-B.; Yue, X.-J. *J. Chem. Soc., Perkin Trans. 1* **1997**, 3053–3058.
- (a) Wolfe, J. P.; Singer, R. A.; Yang, B. H.; Buchwald, S. L. *J. Am. Chem. Soc.* **1999**, *121*, 9550–9561; (b) Barder, T. E.; Walker, S. D.; Martinelli, J. R.; Buchwald, S. L. *J. Am. Chem. Soc.* **2005**, *127*, 4685–4696; (c) Billingsley, K. L.; Anderson, K. W.; Buchwald, S. L. *Angew. Chem., Int. Ed.* **2006**, *45*, 3484–3488; (d) Billingsley, K. L.; Buchwald, S. L. *J. Am. Chem. Soc.* **2007**, *129*, 3358–3366.
- β-Elimination of the *St*-Bu group was also observed in the total synthesis of telomestatin. Cs₂CO₃ promoted β-elimination in the construction of oxazoline. See Ref. 5.